Celldex (CLDX) Price & Analysis

Compare

1,240 Followers

CLDX Stock Chart & Stats

$26.68

-$0.90(-3.26%)

At close: Jan 08 4:00 PM EST

$26.68

-$0.90(-3.26%)

Day’s Range― - ―

52-Week Range$14.40 - $30.50

Previous CloseN/A

Volume733.18K

Average Volume (3M)827.55K

Market Cap

$1.77B

Enterprise Value$1.14B

Total Cash (Recent Filing)$583.22M

Total Debt (Recent Filing)$2.62M

Price to Earnings (P/E)―

Beta1.39

Next Earnings

Mar 02, 2026

EPS Estimate

-1

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.01

Shares Outstanding66,449,470

10 Day Avg. Volume918,853

30 Day Avg. Volume827,547

Financial Highlights & Ratios

PEG Ratio0.64

Price to Book (P/B)2.18

Price to Sales (P/S)231.80

P/FCF Ratio-10.19

Enterprise Value/Market Cap0.65

Enterprise Value/Revenue439.88

Enterprise Value/Gross Profit642.16

Enterprise Value/Ebitda-4.64

Forecast

1Y Price Target

$54.67

Price Target Upside104.91% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

EPS Forecast (FY)-3.66

Revenue Forecast (FY)$2.79M

Bulls Say, Bears Say

Bulls Say

Clinical TrialsCelldex initiates Phase III trial for second urticaria indication, chronic Inducible urticaria.

Drug DevelopmentBarzolvolimab showed profound benefits on multiple secondary measures such as angioedema, QoL, and UCT score, all while maintaining a tolerable safety profile.

Market PotentialThe chronic inducible urticaria (CIndU) indication holds strong market potential with no FDA approved medications.

Bears Say

Cash FlowAnnualized Cash Burn (M) $206.0

Scientific UncertaintyThe scientific question remains on what mechanisms are causing urticaria in patients who don't respond to anti-KIT therapy.

Celldex News

Celldex price target raised to $24 from $21 at Barclays

Barclays raised the firm’s price target on Celldex (CLDX) to $24 from $21 and keeps an Equal Weight...

2d ago

CLDX

These 3 Unknown Stocks Can Double, Say Five-Star Analysts – 12/11/2025

If you’re looking for investment ideas right now, several top-rated Wall Street analysts (each with five-star ratings) believe...

7d ago

CLDX

CNTA

Celldex announces initiation of Phase 3 trial of barzolvolimab

Celldex (CLDX) announced the initiation of its global Phase 3 trial designed to establish the efficacy and safety...

10d ago

CLDX

Celldex Therapeutics Advances Barzolvolimab Study for Chronic Urticaria

Celldex Therapeutics ($CLDX) announced an update on their ongoing clinical study. Study Overview: Celldex Therapeutics is conducting a...

4d ago

CLDX

Celldex Therapeutics Completes Promising Phase 2 Study on Chronic Inducible Urticaria Treatment

Celldex Therapeutics ($CLDX) announced an update on their ongoing clinical study. Celldex Therapeutics has completed a Phase 2...

4d ago

CLDX

Celldex’s Promising Market Opportunity: Buy Rating Backed by Phase III Trial and Revenue Projections

Analyst Edward Nash of Canaccord Genuity maintained a Buy rating on Celldex, retaining the price target of $62.00....

9d ago

CLDX

Celldex’s Strategic Advancement in Phase 3 Trials for Barzolvolimab: A Promising Opportunity in Chronic Inducible Urticaria Treatment

Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Celldex, retaining the price target of $42.00....

9d ago

CLDX

Celldex’s Promising Clinical Progress and Strategic Initiatives Drive Buy Rating

Canaccord Genuity analyst Edward Nash maintained a Buy rating on Celldex yesterday and set a price target of...

1M ago

CLDX

Celldex’s Promising Future: Strong Pipeline and Financial Position Drive Buy Rating

Celldex, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C....

1M ago

CLDX

Celldex price target lowered to $21 from $25 at Barclays

Barclays lowered the firm’s price target on Celldex (CLDX) to $21 from $25 and keeps an Underweight rating...

1M ago

CLDX

Celldex’s Promising Pipeline and Strategic Advancements Justify Buy Rating

LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Celldex today and set a price target of...

1M ago

CLDX

Celldex Therapeutics Reports Q3 2025 Results and Pipeline Progress

Celldex Therapeutics ( ($CLDX) ) has released its Q3 earnings. Here is a breakdown of the information Celldex...

1M ago

CLDX

Optimistic Buy Rating for Celldex Driven by Promising Clinical Developments and Strong Financial Position

TD Cowen analyst Yaron Werber has maintained their bullish stance on CLDX stock, giving a Buy rating on...

1M ago

CLDX

Celldex reports Q3 EPS ($1.01), consensus (89c)

“This quarter, Celldex (CLDX) continued to demonstrate our leadership in the field of mast cell biology, presenting exciting...

1M ago

CLDX

CLDX FAQ

What was Celldex Therapeutics Inc’s price range in the past 12 months?

Celldex Therapeutics Inc lowest stock price was $14.40 and its highest was $30.50 in the past 12 months.

What is Celldex Therapeutics Inc’s market cap?

Celldex Therapeutics Inc’s market cap is $1.77B.

When is Celldex Therapeutics Inc’s upcoming earnings report date?

Celldex Therapeutics Inc’s upcoming earnings report date is Mar 02, 2026 which is in 73 days.

How were Celldex Therapeutics Inc’s earnings last quarter?

Celldex Therapeutics Inc released its earnings results on Nov 10, 2025. The company reported -$1.01 earnings per share for the quarter, missing the consensus estimate of -$0.9 by -$0.11.

Is Celldex Therapeutics Inc overvalued?

According to Wall Street analysts Celldex Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Celldex Therapeutics Inc pay dividends?

Celldex Therapeutics Inc does not currently pay dividends.

What is Celldex Therapeutics Inc’s EPS estimate?

Celldex Therapeutics Inc’s EPS estimate is -1.

How many shares outstanding does Celldex Therapeutics Inc have?

Celldex Therapeutics Inc has 66,449,470 shares outstanding.

What happened to Celldex Therapeutics Inc’s price movement after its last earnings report?

Celldex Therapeutics Inc reported an EPS of -$1.01 in its last earnings report, missing expectations of -$0.9. Following the earnings report the stock price went up 7.499%.

Which hedge fund is a major shareholder of Celldex Therapeutics Inc?

Currently, no hedge funds are holding shares in CLDX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Celldex Stock Smart Score

Underperform

Fundamentals

Return on Equity

-32.44%

Trailing 12-Months

Asset Growth

-21.23%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Celldex Therapeutics Inc

Celldex Therapeutics, Inc. is a biotechnology company focused on developing innovative therapeutics for the treatment of cancer and other diseases. The company specializes in creating monoclonal antibodies and immuno-oncology products, leveraging its proprietary technology platforms to advance its pipeline of candidates aimed at enhancing the immune system's ability to fight tumors. Celldex operates primarily within the healthcare sector, specifically in the biopharmaceutical industry, and is committed to delivering groundbreaking treatment options to improve patient outcomes.

Celldex (CLDX) Earnings & Revenues

Historic Earnings Reports

CLDX Stock 12 Month Forecast

Average Price Target

$54.67

▲(104.91% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"15":"$15","34":"$34","53":"$53","72":"$72","91":"$91"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":90,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$90.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":54.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$54.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$21.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[15,34,53,72,91],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.92,30.849230769230772,35.77846153846154,40.70769230769231,45.63692307692308,50.56615384615385,55.495384615384616,60.424615384615386,65.35384615384615,70.28307692307692,75.21230769230769,80.14153846153846,85.07076923076923,{"y":90,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.92,28.13153846153846,30.343076923076925,32.55461538461539,34.76615384615385,36.97769230769231,39.189230769230775,41.400769230769235,43.612307692307695,45.823846153846155,48.035384615384615,50.24692307692308,52.45846153846154,{"y":54.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.92,25.54153846153846,25.163076923076925,24.784615384615385,24.40615384615385,24.02769230769231,23.64923076923077,23.270769230769233,22.892307692307693,22.513846153846153,22.135384615384616,21.756923076923076,21.37846153846154,{"y":21,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":27.23,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.27,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.49,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.57,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.85,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.71,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.97,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.21,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.19,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.06,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.29,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.73,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.92,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >